Phase 3 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have relapsed or refractory multiple myeloma (meaning the cancer has come back or stopped responding to treatment) and have received at least 1 but no more than 3 previous lines of treatment, which must have included a drug called lenalidomide and at least one other specific type of treatment (either a proteasome inhibitor or an anti-CD38 antibody)
• People whose ability to carry out daily activities is reasonably well preserved, as measured by a standard scoring system called the ECOG scale (score of 2 or lower means someone can care for themselves but may not be able to do heavy physical work) (confirm with trial site)
• People whose multiple myeloma has been confirmed to be getting worse during or after their most recent treatment, based on established medical guidelines

Who may not be able to join:

• People who have previously received certain immune-based treatments that specifically target a protein called BCMA, such as CAR-T cell therapy or bispecific antibody treatments directed at BCMA — however, people who have had a BCMA-targeting antibody-drug conjugate (such as belantamab mafodotin) are not automatically excluded
• People who have been diagnosed with certain related blood or plasma cell conditions, including plasma cell leukaemia, symptomatic amyloidosis, Waldenström macroglobulinemia, or POEMS syndrome
• People whose multiple myeloma has spread to the central nervous system (the brain or spinal cord), including the membranes surrounding the brain
• People with a history of a degenerative neurological condition, a brain infection called Progressive Multifocal Leukoencephalopathy (PML), or a movement disorder affecting the central nervous system

Important: Always verify eligibility with the trial site directly before applying.